Introduction {#s1}
============

Fibrotic idiopathic interstitial pneumonias (f-IIPs) (idiopathic pulmonary fibrosis (IPF) and fibrotic nonspecific interstitial pneumonitis (f-NSIP)) are interstitial lung diseases (ILDs) associated with poor prognosis and impaired daily life activities \[[@C1]\]. f-IIP patients display persistent and severe dyspnoea, exercise intolerance, and poor health-related quality of life (QoL) \[[@C2]\]. Patients with chronic respiratory diseases, including ILDs, have been shown to respond well to pulmonary rehabilitation, a validated and widely used method to improve dyspnoea, exercise tolerance, QoL and mood \[[@C3]--[@C5]\]. However, the beneficial effects of pulmonary rehabilitation in patients with ILDs have mainly been established in short-term studies (1--4 weeks) and reports of medium- to long-term effects (6--12 months) have been inconsistent, particularly in patients with progressively worsening fibrosing ILDs \[[@C5], [@C6]\]. For example, a recent meta-analysis reported no detectable improvements in exercise tolerance (distance in the 6-min walk test (6MWT)) after long-term follow-up (6 months) of f-IIP patients who underwent a 6- to 24-week pulmonary rehabilitation programme \[[@C7]\]. Similarly, a randomised study of 142 patients by D[owman]{.smallcaps} *et al.* \[[@C8]\] found no benefit on exercise tolerance, QoL or depression scores at 6 months after completion of an 8-week pulmonary rehabilitation programme. However, in their study, R[yerson]{.smallcaps} *et al.* \[[@C9]\] reported improvements in these same parameters at 6 months after 39 patients completed a 6- to 9-week pulmonary rehabilitation programme. Moreover, while the results were not statistically significant, V[ainshelboim]{.smallcaps} *et al.* \[[@C10]\] showed a trend towards stabilisation of exercise tolerance and QoL in 14 patients at 11 months after a 3-month pulmonary rehabilitation programme, whereas these parameters deteriorated in the control group who did not participate in pulmonary rehabilitation.

In an effort to clarify the benefits of pulmonary rehabilitation in patients with f-IIP, we investigated the long-term effect of a 2-month home-based pulmonary rehabilitation program in a large cohort of patients with IPF and f-NSIP.

Patients and methods {#s2}
====================

Patients {#s2a}
--------

Between December 2011 and December 2017, 234 patients with a diagnosis of f-IIP were referred to our reference centre for rare pulmonary diseases for a diagnosis and medical decision based on multidisciplinary discussion with radiologists and pathologists. The inclusion criteria were 1) a diagnosis of IPF or f-NSIP according to the international consensus guidelines \[[@C11]\] and 2) no acute exacerbation in the 3 months preceding enrolment. Exclusion criteria were dementia or poorly controlled psychiatric illness, neurological sequelae, or bone and joint disease preventing physical activity. Of the 234 patients, 112 (70 males and 42 females; all Caucasian) gave written informed consent to participate in a home-based pulmonary rehabilitation programme. The study was performed in accordance with the local board on medical ethics. Approval for the use of the data was provided by the Institutional Review Board of the French Learned Society for Pulmonology (CEPRO 2011-039).

Pulmonary function tests and the 6MWT were performed at baseline; all other tests were performed at the patient\'s home throughout the study (see Assessments section). Forced vital capacity (FVC), forced expiratory volume in 1 s and total lung capacity were measured by spirometry and plethysmography with a Jaeger-Masterlab cabin (Vyaire Medical, Hoechberg, Germany), and single-breath diffusing capacity of the lung for carbon monoxide (*D*~LCO~ (mL·min^−1^·mmHg^−1^)) was measured and corrected for haemoglobin concentration. Values are expressed as percentages of the predicted normal values \[[@C12]\]. Patients with FVC ≥50% predicted and *D*~LCO~ ≥30% predicted were classified as having mild-to-moderate disease, and patients with FVC \<50% predicted and/or *D*~LCO~ \<30% predicted were classified as having severe disease \[[@C13]\]. The 6MWT was performed in accordance with international recommendations \[[@C14]\].

Study design {#s2b}
------------

This was an observational monocentric study with retrospective analysis of structurally captured data. The home-based pulmonary rehabilitation programme has been described in detail elsewhere \[[@C15]\]. Briefly, patients received one supervised in-home 90-min session per week for 2 months. The sessions were tailored based on an initial educational needs assessment, and comprised endurance physical exercise on a cycle ergometer, training in physical activities of daily living, strengthening exercises, therapeutic patient education, psychosocial support, and motivational communication to facilitate health behaviour changes and self-management. Each weekly session was conducted under the direct supervision of a team member, but patients were expected to perform a personalised endurance physical exercise plan, unsupervised, on the other days of the week. Follow-up home visits were performed bimonthly for 12 months after the end of the 2-month pulmonary rehabilitation programme. A detailed accident protocol was included in each patient\'s pulmonary rehabilitation agreement.

Assessments {#s2c}
-----------

Patients were evaluated at home before (±7 days; T~0~), immediately (±7 days) after (T~2~), 6 months (±1 month) after (T~8~) and 12 months (±1 month) after (T~14~) the end of the 2-month pulmonary rehabilitation programme. Exercise tolerance was evaluated using the 6-min stepper test (6MST), as previously described \[[@C16]\]. This test was selected because it is feasible for home use in patients with pulmonary disease and it has been verified to detect improved functional capacity after pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD) \[[@C17]\]. A change of 40 strokes (1 stroke=a half-cycle up or down) has been proposed as the minimal clinically important difference (MCID) for COPD patients \[[@C18]\]. Psychological state was determined using the Hospital Anxiety and Depression Scale (HADS) \[[@C19]\]. This questionnaire comprises 14 items (seven each for anxiety and depression), with responses being scored on a scale of 0--3 to indicate symptom frequency (minimum and maximum subscores of 0 and 21; lower is better). For both subscores, a change of 1.5 points is considered the MCID for COPD patients \[[@C20]\]. The Visual Simplified Respiratory Questionnaire (VSRQ) was initially developed for COPD patients, and is a validated and reliable questionnaire to assess health-related QoL \[[@C21]\]. It comprises eight visual analogue scales ranging from 0 to 10 (minimum and maximum scores of 0 and 80; higher is better). The MCID for COPD patients is considered 3.4 points.

Statistical analysis {#s2d}
--------------------

Categorical variables are expressed as frequencies and percentages, and continuous variables are expressed as means with standard deviation. Normality of distribution was checked graphically and using the Shapiro--Wilk test. Comparisons of groups according to disease severity (mild-to-moderate *versus* severe) and disease type (IPF *versus* f-NSIP) were performed using the t-test for baseline continuous variables and the Chi-squared test for sex ratio.

Changes in study outcomes over time (6MST strokes, HADS scores and VSRQ score) were assessed using a linear mixed model with time as a fixed effect and patient as a random effect. When the time effect was significant, *post hoc* tests were performed to compare the baseline value and each follow-up assessment. Normality of the model residuals was checked for each outcome. Changes in study outcomes according to disease severity or type were assessed by including a time interaction term in a linear mixed model. All analyses were repeated for the cohort who completed the 12-month follow-up (n=62; sensitivity analysis). Results are expressed as means and 95% confidence intervals. All analyses were performed using a two-tailed test with an α-level of 0.05. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results {#s3}
=======

The clinical and functional baseline characteristics of the patients included in the study are summarised by disease severity and type in [table 1](#TB1){ref-type="table"}. Of the total cohort of 112 patients, 21% were treated with anxiolytics and/or antidepressants, 34% were on long-term oxygen therapy, and 53% were on ambulatory oxygen. Disease severity was considered mild-to-moderate in 65 patients and severe in 47 patients. All of the baseline characteristics except age and sex were significantly different between these two groups.

###### 

Baseline characteristics of patients

                                         **f-IIP**   **p-value**    **IPF**    **f-NSIP**   **p-value**              
  ------------------------------------- ----------- ------------- ----------- ------------ ------------- ----------- -------
  **Patients**                              112          65           47                        61           51      
  **Age years**                          66.8±10.2    67.9±9.3     65.1±11.3      0.15       66.8±10.0    66.7±10.6   0.97
  **Male/female**                          70/42        41/24        29/18        0.88         46/15        24/27     0.002
  **BMI kg·m^−2^**                       27.4±4.8     28.8±5.0     25.4±3.6     \<0.001      27.8±4.3     27.0±5.3    0.36
  **FVC % pred**                         69.7±19.7    78.6±17.1    57.4±16.2    \<0.001      68.6±18.0    71.1±21.6   0.52
  **FEV**~**1**~ **% pred**              70.1±19.4    78.3±17.2    59.3±16.8    \<0.001      69.6±18.3    70.8±20.9   0.74
  **TLC % pred**                         67.6±15.2    73.8±15.0    58.7±10.4    \<0.001      66.7±14.4    68.7±16.2   0.55
  ***D***~**LCO**~ **% pred**            35.9±12.7    42.4±10.3    23.9±6.5     \<0.001      33.4±9.8     39.1±15.1   0.033
  **6MWT distance m**                     357±116      391±109      303±109     \<0.001       370±113      338±120    0.20
  **6MWT nadir *S***~**pO~2~**~ **%**      83±7         86±6         80±7       \<0.001        82±7         86±7      0.011
  **6MST strokes**                        364±150      413±151      292±116     \<0.001       371±144      356±157    0.63
  **HADS score**                         15.2±7.0     14.1±6.7     16.6±7.4      0.067       15.0±6.7     15.5±7.5    0.70
  **VSRQ score**                         37.3±16.4    40.8±15.0    32.3±17.1     0.007       37.6±16.4    36.9±16.5   0.82

Data are presented as n or mean±[sd]{.smallcaps}, unless otherwise stated. f-IIP: fibrosing idiopathic pulmonary pneumonia; IPF: idiopathic pulmonary fibrosis; f-NSIP: fibrotic nonspecific interstitial pneumonitis; BMI: body mass index; FVC: forced vital capacity; FEV~1~: forced expiratory volume in 1 s; TLC: total lung capacity; *D*~LCO~: diffusing lung capacity of the lung for carbon monoxide; 6MWT: 6-min walk test; *S*~pO~2~~: arterial oxygen saturation measured by pulse oximetry; 6MST: 6-min stepper test; HADS: Hospital Anxiety and Depression Scale; VSRQ: Visual Simplified Respiratory Questionnaire.

61 of the patients were diagnosed with IPF and 51 with f-NSIP. The proportion of males in the IPF group (male/female 46/15) was significantly greater than that in the f-NSIP group (male/female 24/27) ([table 1](#TB1){ref-type="table"}). Gas exchange parameters (*D*~LCO~ and nadir arterial oxygen saturation measured by pulse oximetry during the 6MWT) were significantly lower in the IPF group than in the f-NSIP group, but there were no other significant differences in baseline parameters between the two disease groups.

The disposition of the 112 patients is summarised in [figure 1](#F1){ref-type="fig"}. 27 patients died and five underwent lung transplantation during the 14-month study. No adverse events or deaths attributable to the pulmonary rehabilitation or exercise retraining were recorded during or after the programme. In total, 101 patients (90.2%) completed the pulmonary rehabilitation programme and 62 (55.4%) completed all follow-up visits. Of the 50 patients who did not attend the 12-month follow-up visit, 20 had mild-to-moderate disease and 30 had severe disease. Patients who dropped out had more severe disease at baseline than those who completed the study, according to their functional characteristics ([supplementary table S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00045-2019.figures-only#fig-data-supplementary-materials)).

![Flow diagram of patient disposition.](00045-2019.01){#F1}

As shown in [table 2](#TB2){ref-type="table"}, exercise tolerance (6MST strokes), QoL (VSRQ score), anxiety (HADS Anxiety score), and overall anxiety and depression (HADS Total score) were all significantly improved at T~2~ (the end of the 2-month programme) and at both T~8~ and T~14~ (6- and 12-month follow-up, respectively) compared with T~0~. After 12 months, the mean changes were 41.6 (95% CI 15.2--68.0) strokes for the 6MST, −1.5 (95% CI −2.9--0.1) for the HADS Anxiety score and 4.2 (95% CI 0.6--7.7) for the VSRQ score. In sensitivity analyses of the 62 patients who completed the T~14~ visit, the 6MST strokes and HADS Anxiety score were significantly improved, whereas the HADS Depression score and VSRQ score did not change ([table 3](#TB3){ref-type="table"}).

###### 

Evaluation of exercise tolerance, anxiety, depression and quality of life before (T~0~), immediately after (T~2~), 6 months after (T~8~) and 12 months after (T~14~) the end of the pulmonary rehabilitation programme for all patients

                               **T~0~**      **T~2~**        **T~8~**       **T~14~**    **Global p-value**
  --------------------------- ----------- --------------- --------------- ------------- --------------------
  **Patients**                    112           101             76             62       
  **6MST strokes**              364±150    417±169\*\*\*    452±173\*\*    453±186\*\*        \<0.001
  **HADS Total score**         15.2±7.0    13.5±6.4\*\*    12.4±6.7\*\*    12.3±6.4\*          0.008
  **HADS Anxiety score**        8.6±4.5     7.5±3.9\*\*    7.0±3.8\*\*\*   7.0±4.2\*\*         0.001
  **HADS Depression score**     6.6±3.8       5.9±3.5         5.4±3.8        5.3±3.3            0.23
  **VSRQ score**               37.3±16.4   42.7±15.3\*\*     42.1±16.5     45.0±16.7\*         0.013

Data are presented as n or mean±[sd]{.smallcaps}, unless otherwise stated. 6MST: 6-min stepper test; HADS: Hospital Anxiety and Depression Scale; VSRQ: Visual Simplified Respiratory Questionnaire. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001, significant difference from T~0~.

###### 

Evaluation of exercise tolerance, anxiety, depression, and quality of life before (T~0~), immediately after (T~2~), 6 months after (T~8~) and 12 months after (T~14~) the end of the pulmonary rehabilitation programme for the 62 patients who completed the study

  **Variable**                 **T~0~**      **T~2~**         **T~8~**       **T~14~**    **Global p-value**
  --------------------------- ----------- --------------- ---------------- ------------- --------------------
  **Patients**                    62            62               62             62       
  **6MST strokes**              408±145    472±150\*\*\*   462±167\*\*\*    453±186\*\*        \<0.001
  **HADS Total score**         13.6±6.9      12.3±6.2      11.2±5.9\*\*\*    12.3±6.4           0.009
  **HADS Anxiety score**        8.0±4.5      7.2±4.0\*     6.5±3.6\*\*\*     7.0±4.2\*          0.002
  **HADS Depression score**     5.6±3.3       5.1±3.0         4.7±3.3         5.3±3.3            0.24
  **VSRQ score**               42.0±16.6     45.9±14.4       45.0±15.8       45.0±16.7           0.21

Data are presented as n or mean±[sd]{.smallcaps}, unless otherwise stated. 6MST: 6-min stepper test; HADS: Hospital Anxiety and Depression Scale; VSRQ: Visual Simplified Respiratory Questionnaire. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001, significant difference from T~0~.

Disease severity and subtype had no effects on the 6MST strokes, HADS scores or VSRQ score ([figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}), and this was also true for the sensitivity analyses.

![Evaluation of exercise tolerance (6-min stepper test (6MST)), quality of life (Visual Simplified Respiratory Questionnaire (VSRQ)) and mood (Hospital Anxiety and Depression Scale (HADS)) in the fibrosing idiopathic pulmonary pneumonia patient population and the subset who completed the study according to disease severity. a, b) Number of strokes performed in the 6MST, c, d) VSRQ score and e, f) HADS score were assessed for all patients (a, c and e) and the 62 patients who completed the study (b, d and f) before (T~0~), immediately after (T~2~), 6 months after (T~8~) and 12 months after (T~14~) the end of the pulmonary rehabilitation programme. Data are presented as mean±[se]{.smallcaps}. The p-value for the interaction between time and disease severity (*i.e.* change in the variable with time compared between the mild-to-moderate and severe disease groups) is indicated.](00045-2019.02){#F2}

![Evaluation of exercise tolerance (6-min stepper test (6MST)), quality of life (Visual Simplified Respiratory Questionnaire (VSRQ)) and mood (Hospital Anxiety and Depression Scale (HADS)) in the patients with idiopathic pulmonary fibrosis (IPF) and fibrotic nonspecific interstitial pneumonitis (f-NSIP). a, b) Number of strokes performed in the 6MST, c, d) VSRQ score and e, f) HADS score were assessed for the subsets of patients with IPF (n=61) (a, c and e) and NSIP (n=51) (b, d and f) before (T~0~), immediately after (T~2~), 6 months after (T~8~) and 12 months after (T~14~) the end of the pulmonary rehabilitation programme. Data are presented as mean±[se]{.smallcaps}. The p-value for the interaction between time and disease aetiology (*i.e.* change in the variable with time compared between the disease groups) is indicated.](00045-2019.03){#F3}

Discussion {#s4}
==========

Our study shows significant long-term (12 months) benefits of a 2-month home-based pulmonary rehabilitation programme for f-IIP patients with bimonthly visits during follow-up. The main result of our pragmatic study is that the improvements in exercise tolerance and anxiety observed at the end of the pulmonary rehabilitation programme were maintained for 12 months. Interestingly, these benefits were experienced by all patients, even those with severe f-IIP.

Since 2008, several studies have established that pulmonary rehabilitation is safe, and has immediate beneficial effects on exercise tolerance, QoL and dyspnoea in patients with ILDs \[[@C5], [@C8], [@C22]--[@C25]\]. However, relatively few studies have examined the medium- and long-term benefits of pulmonary rehabilitation in f-IIP patients, and the results have varied considerably. For example, the randomised study of D[owman]{.smallcaps} *et al.* \[[@C8]\] found that benefits in exercise tolerance, QoL and depression were not sustained at 6 months after exercise training, whereas the cohort studied by R[yerson]{.smallcaps} *et al.* \[[@C9]\] showed sustained benefits in the same parameters at the same time-point after pulmonary rehabilitation. Additionally, the f-IIP patients studied by V[ainshelboim]{.smallcaps} *et al*. \[[@C10]\] showed a tendency towards stabilisation of 6MWT and QoL benefits at 11 months post-pulmonary rehabilitation compared with baseline, whereas these parameters deteriorated in the control group. The conflicts between our study and those of V[ainshelboim]{.smallcaps} *et al*. \[[@C10]\] and D[owman]{.smallcaps} *et al.* \[[@C8]\] may be due to differences in patient cohorts, even though the latter study included patients with better prognosis than our f-IIP patients (*e.g.* asbestosis, sarcoidosis, hypersensitivity pneumonitis) \[[@C8]\]. Our results are consistent with those of a recent study by P[erez-]{.smallcaps}B[ogerd]{.smallcaps} *et al.* \[[@C26]\], who reported that pulmonary rehabilitation-induced improvements in exercise tolerance, health status and muscle force in patients with ILDs were maintained at 1-year follow-up. However, it should be noted that the study of P[erez-]{.smallcaps}B[ogerd]{.smallcaps} *et al.* \[[@C26]\] differed from ours in several respects: it included fewer patients with IIP (10 out of 30), the pulmonary rehabilitation programme was of 6 months duration (which is unusually long) and the "12-month" assessment was actually performed 6 months after the end of the 6-month pulmonary rehabilitation programme. In addition, the study by P[erez-]{.smallcaps}B[ogerd]{.smallcaps} *et al.* \[[@C26]\] used the 6MWT to assess exercise endurance, whereas we employed the 6MST. The latter test is more practical than the 6MWT, easy to perform at home \[[@C17]\], reproducible and sensitive. Moreover, the number of strokes in the 6MST correlates well with the distance travelled in the 6MWT in ILD patients \[[@C16]\].

Anxiety and depression are common in patients with ILDs. In a study of 50 patients with f-IIP (29 IPF and 21 NSIP), 54% had anxiety and 28% had depression (HADS subscores ≥8 for both) \[[@C27]\]. In another study, 59 out of 118 (49%) IPF patients had a score greater than the cut-off value of 15 on the Wakefield Self-assessment of Depression Inventory questionnaire \[[@C28]\]. Home-based pulmonary rehabilitation may improve anxiety, depression and psychological health by breaking the vicious circle of negative emotions, unpleasant breathing sensations and poor exercise performance \[[@C29]\].

We assessed QoL in our f-IIP patients using the VSRQ, a short questionnaire that has been validated in COPD patients \[[@C21]\], but not in ILD patients. We have used the VSRQ since the beginning of our home-based pulmonary rehabilitation programmes, which initially included predominantly COPD patients \[[@C15]\], and we continue to use it with other patients because it is informative and easy to use. We found a significant improvement above the MCID of 3.4 points that persisted for at least 12 months. Several additional studies have identified pulmonary rehabilitation-derived improvements in QoL, including one of 440 ILD patients (202 IPF, 21 NSIP and 217 other ILDs), but those studies used the 36-item Short-Form Health Survey, which includes physical and psychological components \[[@C5], [@C10], [@C30]\].

Our finding that pulmonary rehabilitation benefits are sustained for at least 12 months has not previously been demonstrated in f-IIP patients. We speculate that the home-based aspect was a crucial factor in this success. First, on unsupervised days, the patients could select whichever physical activities they found most enjoyable, which is undoubtedly easier at home. A patient is more likely to integrate physical activities into his/her daily life and to pursue them long term if they are involved in developing their own individualised action plan that takes into account their preferences and available facilities, is based on activities of daily living, and is combined with a home-based exercise retraining programme \[[@C31]\]. Second, the home setting allowed the patient\'s partner and/or caregivers to become involved. Finally, the bimonthly visit to the patient\'s home allowed the specialised pulmonary rehabilitation team to address difficulties, demonstrate solutions and provide motivational reinforcement, not only to the patient but also their partner and/or caregivers. Pulmonary rehabilitation gains can only be sustained if the patient also receives therapeutic education and behavioural/motivational support. Several studies have confirmed the interest of ILD patients in therapeutic education \[[@C32]\]. The motivational and behavioural aspects of a pulmonary rehabilitation programme \[[@C33]\] also give the patient confidence, and establish a faster therapeutic alliance between the patient and the rehabilitation team \[[@C34]\].

Although f-IIPs are progressive and fatal diseases with a median survival time of \<4 years after diagnosis, treatment advances show encouraging signs of slowing disease progression and declining pulmonary function \[[@C35]\]. Only 36 patients (32%) had dropped out of our study after 6 months, comparable to the findings of R[yerson]{.smallcaps} *et al.* \[[@C9]\] (30% at 6 months), suggesting that pulmonary rehabilitation could be a meaningful addition to the available treatment options. Pulmonary rehabilitation is currently the safest and most effective nondrug treatment known to improve dyspnoea, depression and anxiety, and should be offered to all f-IIP patients as part of a broader supportive care plan \[[@C3], [@C11], [@C29]\]. Particularly when prescribed soon after diagnosis, pulmonary rehabilitation could not only improve exercise tolerance and QoL but could also assist the patient, partner and/or caregiver in initiating the difficult, and often protracted, work of acceptance and end-of-life planning. This is particularly important, since palliative care is requested but rarely implemented in patients with IPF before the end of life \[[@C36]\].

There are several limitations to our study. Most patients received immunosuppressive agents, corticosteroids (for f-NSIP) and/or antifibrotic agents (for IPF), which is a potential confounding factor. We could not standardise the treatments or take them into account during data analysis because the treatments were implemented after the beginning of the pulmonary rehabilitation programme and the doses were adjusted according to individual patient needs. Although the VSRQ has not been validated in ILD patients, it is an easy method for patients to assess their respiratory-related QoL and it has been validated in studies assessing pulmonary rehabilitation programmes in patients with a variety of respiratory disorders, including COPD and severe asthma. We do not know how many more days the participants exercised by themselves, within and after the 2-month period. However, an important aspect of our patient\'s overall care is to trust that they are motivated to make long-term changes in their health behaviour (with the help of their entourage). This is routinely accomplished by motivating them, valuing the progress made during follow-up appointments, helping them to make adjustments where necessary and giving them confidence in their ability to act (empowerment and self-management). Lastly, the study was not randomised, and patients selected the home-based design according to their preference and/or the distance to the nearest pulmonary rehabilitation centre. This could represent a recruitment bias. However, home-based pulmonary rehabilitation has proven long-lasting benefits \[[@C15], [@C37]--[@C39]\] and caters well to patients who have limited mobility, lack motivation to participate at a pulmonary rehabilitation centre, do not wish to be hospitalised, have transportation problems, live a long distance from the nearest centre or do not wish to leave their home \[[@C3], [@C40]\].

In conclusion, home-based pulmonary rehabilitation provided long-term benefits in exercise tolerance, QoL and mood for patients with f-IIP. Pulmonary rehabilitation at home offers an alternative to centre-based pulmonary rehabilitation programmes (in-hospital or outpatient), greatly expanding the number of patients with access to care, supervised by a transdisciplinary team qualified in this field.
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